세계의 갑상선 질환 치료 시장 규모 : 약제 유형별, 질환별, 투여 경로별, 지역 범위별 예측

Thyroid Disorder Treatment Market Size And Forecast

Thyroid Disorder Treatment Market size was valued at USD 2.2 Billion in 2024 and is projected to reach USD 2.8 Billion by 2032 growing at a CAGR of 3.17% from 2026 to 2032.

• Thyroid disorder treatment is controlling conditions such as hypothyroidism and hyperthyroidism using medications such as levothyroxine or antithyroid agents. These treatments are intended to restore thyroid hormone levels and reduce symptoms.
• Radioactive iodine and thyroid hormone replacement therapy are currently used to treat hyperthyroidism and hypothyroidism, respectively. Surgery may be considered in severe situations. Regular monitoring enables efficient management.
• In the future, treatments may center on customized medicine, targeted therapeutics and advances in gene editing. Emerging medicines may provide more precise management, improving outcomes while minimizing side effects.

Global Thyroid Disorder Treatment Market Dynamics

The key market dynamics that are shaping the global Thyroid Disorder Treatment Market include:

Key Market Drivers:

• Increasing Incidence: Rising occurrences of thyroid problems, including as hypothyroidism and hyperthyroidism, are driving need for better therapies, aided by increasing detection rates and awareness.
• Advancements in Treatment: Pharmaceutical innovations, such as improved medication formulations and tailored therapies, improve treatment efficacy and appeal, promoting market growth.
• Aging Population: The expanding older population, which is more prone to thyroid problems, adds to the demand for therapeutic alternatives suited to age-related thyroid conditions.
• Healthcare Access: Increasing healthcare infrastructure and access in emerging countries increases diagnostic and treatment availability, boosting market growth in previously neglected areas.

Key Challenges:

• Lack of Awareness: Inadequate knowledge and education about thyroid problems might result in delayed diagnosis and treatment, diminishing market potential.
• Limited Access: Inadequate healthcare infrastructure in rural or disadvantaged areas might impede diagnosis and treatment, limiting market growth.
• Adverse Effects and Problems: Treatment side effects and problems from thyroid disorders might lead to patient noncompliance and reduce overall market acceptance.

Key Trends:

• Advanced Diagnostics: Improvements in advanced diagnostic instruments and imaging techniques have resulted in earlier and more accurate detection of thyroid problems.
• Biologics and Targeted Therapies: The development and implementation of biologic medications and targeted therapies to address the underlying causes of thyroid problems, hence providing new therapeutic choices.
• Telemedicine and Digital Health: Telemedicine and digital health technologies are increasingly being used for remote monitoring and management, hence enhancing patient access to care and treatment adherence.

Global Thyroid Disorder Treatment Market Regional Analysis

Here is a more detailed regional analysis of the global Thyroid Disorder Treatment Market:

North America:

• According to Verified Market Research, North America is expected to dominate the global Thyroid Disorder Treatment Market.
• North America is likely to lead the worldwide thyroid disease treatment market due to its sophisticated healthcare infrastructure, high prevalence of thyroid disorders and major expenditure in R&D.
• The region's strong medical facilities and high levels of awareness help to maintain its leadership position, which is reinforced by ongoing advancements in treatment and diagnostics.

Asia Pacific:

• According to Verified Market Research, Asia Pacific is fastest growing region in global Thyroid Disorder Treatment Market.
• Asia-Pacific is the fastest-growing area in the worldwide thyroid disease treatment market, due to growing healthcare investments, rising thyroid condition prevalence and greater access to modern medical technologies. The region's high economic growth and improved healthcare facilities help to boost market expansion.

Global Thyroid Disorder Treatment Market: Segmentation Analysis

The Global Thyroid Disorder Treatment Market is segmented on the basis of Drug Type, Disease, Route of Administration, and Geography.

Thyroid Disorder Treatment Market, By Drug Type

• Levothyroxine
• Liothyronine
• Propylthiouracil
• Imidazole-based Compounds
• Beta-blockers

Based on Drug Type, The market is segmented into Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based Compounds, Beta-blockers. Levothyroxine is the most common drug type in the global thyroid disease treatment market, used to treat hypothyroidism and maintain normal thyroid hormone levels.

Thyroid Disorder Treatment Market, By Disease

• Hypothyroidism
• Hyperthyroidism

Based on Disease, The market is segmented into Hypothyroidism and Hyperthyroidism. Hypothyroidism dominates the worldwide thyroid problem treatment market due to its higher prevalence than hyperthyroidism. The requirement for lifelong hormone replacement therapy creates increasing market demand and treatment possibilities.

Thyroid Disorder Treatment Market, By End-User

• Oral
• Intravenous

Based on End-User, The market is segmented into Oral and Intravenous. The oral category leads the global thyroid disease therapy market due to its convenience, ease of administration and patient preference. Oral medicines are commonly used to treat thyroid problems.

Key Players

The "Global Thyroid Disorder Treatment Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are AbbVie, Inc., Mylan N.V., Merck & Co., Inc., Pfizer, Inc., Abbott Laboratories, Allergan plc, Bayer AG, Novartis AG, Sanofi S.A., GlaxoSmithKline plc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

• Global Thyroid Disorder Treatment Market Recent Developments
• In December 2023, Aspen Global Incorporated, a subsidiary of Aspen Pharmacare Holdings Limited, reached an agreement with Sandoz AG to acquire its Chinese business. This strategic move was consistent with Aspen's strategy goal of increasing its footprint in China by using Sandoz's proven portfolio, infrastructure and experienced team for future growth in the region.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL THYROID DISORDER TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL THYROID DISORDER TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL THYROID DISORDER TREATMENT MARKET, BY DRUG TYPE

• 5.1 Overview
• 5.2 Levothyroxine
• 5.3 Liothyronine
• 5.4 Propylthiouracil
• 5.5 Imidazole-based Compounds
• 5.6 Beta-blockers

6 GLOBAL THYROID DISORDER TREATMENT MARKET, BY DISEASE

• 6.1 Overview
• 6.2 Hypothyroidism
• 6.3 Hyperthyroidism

7 GLOBAL THYROID DISORDER TREATMENT MARKET, BY END-USER

• 7.1 Overview
• 7.2 Oral
• 7.3 Intravenous

8 GLOBAL THYROID DISORDER TREATMENT MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL THYROID DISORDER TREATMENT MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 AbbVie, Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Mylan N.V.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Merck & Co., Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Pfizer, Inc.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Abbott Laboratories
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Allergan plc
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Bayer AG
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Novartis AG
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Sanofi S.A.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 GlaxoSmithKline plc.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research